Table 1.
Distribution of study variables across oxytocin and placebo groups at baseline
| Study Variable | Oxytocin n = 48 |
Placebo n = 51 |
p-value | ||
|---|---|---|---|---|---|
| M | SD | M | SD | ||
| Demographics | |||||
| Age (yrs) | 32 | 10.2 | 34 | 11.2 | 0.34 |
| BMI (kg/m2) | 23.9 | 2.8 | 23.6 | 3.1 | 0.62 |
| Educational attainment (yrs) | 16.6 | 3.0 | 16.6 | 2.1 | 0.93 |
| Affect (sum score) | |||||
| Trait negative affect | 16.4 | 5.3 | 14.7 | 4.8 | 0.09 |
| Trait positive affect | 22.5 | 24.4 | 24.6 | 6.8 | 0.12 |
| Trait anxiety | 23.0 | 6.6 | 21.6 | 5.7 | 0.25 |
| Trait anger | 21.7 | 7.6 | 19.9 | 6.4 | 0.21 |
| Physiological* | |||||
| CO (L/min) | 7.2 | 2.3 | 6.8 | 2.1 | 0.44 |
| PEP (ms) | 112.2 | 11.8 | 110.1 | 10.9 | 0.38 |
| RSA (ms2) | 6.5 | 1.1 | 6.2 | 1.3 | 0.25 |
| Estradiol (pg/mL) | 3.9 | 3.0 | 4.1 | 3.3 | 0.76 |
*
Note. average over 6 minutes of baseline. CO indicates cardiac output; PEP indicates pre-ejection period (we use this measure to calculate ventricle contractility); RSA indicates respiratory sinus arrhythmia.